- About Overview
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Assistant Deans
- Associate Deans
- Education Unit
- Office of Academic Affairs
- Office of Finance and Administration
- Office of Planning and Communications
- Org chart
- Patient Care
Drilling down to the details of opioid signaling
Study sheds light on molecular basis of pain relief from opioid drugs
By Levi Gadye / Wed Jul 11, 2018
Antoine Koehl (Manglik lab)
Despite using opioids for centuries for pain management, we still don’t have a complete understanding of how drugs like morphine and oxycodone actually work. And that’s a problem for patients, who must weather side effects that can range from nausea and constipation to cognitive impairment, addiction, and, at high doses, even death.
When opioid drugs enter the bloodstream, they stimulate "µ-opioid receptors" on the surface of neurons in the brain. These receptors are part of a large class of proteins, called G-protein coupled receptors (GPCRs), which relay signals from outside and into the cell by stimulating partner molecules, called G-proteins, on the inside of the cell. Yet the details of how opiates produce their effects, wanted and unwanted, via GPCRs and G-proteins, have remained elusive.
Recent findings, led in part by Aashish Manglik, MD, PhD, have now revealed how the µ-opioid receptor engages with a particular G-protein as the first molecular step toward quelling pain. The researchers used a technique called cryo-electron microscopy, or cryo-EM, to directly observe an opioid drug activating the receptor, which then activates its G-protein. The study was published on June 13 in Nature.
Manglik is a faculty member in the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry, and he holds a joint appointment in the School of Medicine's Department of Anesthesia. He carried out this research as a graduate student and Distinguished Fellow at Stanford University.
“We’ve essentially captured this signaling event in the act,” Manglik explained to UCSF News. “These new atomic-level images will hopefully enable us to rationally design compounds that target different aspects of opioid signaling in the brain, with hopes of identifying new, safer painkillers.”
CryoEM Study Captures Opioid Signaling in the Act (UCSF News Center)
About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school in the American West. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.